Few data are currently available in the literature on pancreatic adenocarcinoma in France. About 8,000 new cases each year in France. The 5-year survival for all stages combined is \<5%. This is the only digestive cancer in which mortality / incidence ratio is 98%. Epidemiological characteristics at diagnosis, the impact on the survival of recent advances related to surgery, adjuvant chemotherapy and new standard forms of adjuvant chemotherapy (FOLFIRINOX) are mispriced in real life. The development of new drugs and the development of Phase II and III require a better understanding of the state of this disease in the country. The main objective is to describe the characteristics of the pancreatic adenocarcinoma at diagnosis in France and make an inventory of diagnostic practices and support.
Study Type
OBSERVATIONAL
Enrollment
1,204
CH de Jolimont
Jolimont, Belgium
CH Gabriel Martin
Saint-Paul, La Réunion, France
CHIAP
Aix-en-Provence, France
CH Angoulême
Angoulême, France
CH d'Aubenas
Aubenas, France
CH Auch
Auch, France
CH Robert Ballanger
Aulnay-sous-Bois, France
CH Avignon
Avignon, France
CH Bagnols sur Ceze
Bagnols-sur-Cèze, France
CH Bayeux
Bayeux, France
...and 56 more locations
Survival
Time frame: patient death (following during 5 year)
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.